Riboflavin-ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells

Transfusion

Volumn 56, Issue 4, 2016, Pages 863-872

  Tormey, Christopher A ^a,b   Santhanakrishnan, Manjula ^a   Smith, Nicole H ^c   Liu, Jingchun ^a   Marschner, Susanne ^d   Goodrich, Raymond P ^d   Hendrickson, Jeanne E ^a,c,e  

^a Department of Laboratory Medicine ^*  (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE ANTIGEN; FLUORESCENT DYE; RIBOFLAVIN; ALLOANTIBODY; KEL PROTEIN, HUMAN; MEMBRANE PROTEIN; METALLOPROTEINASE;

ALLOIMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; COOMBS TEST; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; IMMUNOGENICITY; LIGHT EXPOSURE; MOUSE; NONHUMAN; PATHOGEN REDUCTION SYSTEM; TRANSGENIC MOUSE; ULTRAVIOLET RADIATION; ANIMAL; ANTIBODY PRODUCTION; BLOOD STORAGE; BLOODBORNE BACTERIUM; C57BL MOUSE; DRUG EFFECTS; IMMUNOLOGY; INSTRUMENT STERILIZATION; METABOLISM; PROCEDURES; RADIATION RESPONSE;

ANIMALS; ANTIBODY FORMATION; BLOOD PRESERVATION; BLOOD-BORNE PATHOGENS; ERYTHROCYTES; HUMANS; ISOANTIBODIES; MEMBRANE GLYCOPROTEINS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RIBOFLAVIN; STERILIZATION; ULTRAVIOLET RAYS;

EID: 84963607039     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13432     Document Type: Article

References (34)

1. Snyder EL, Stramer SL, Benjamin RJ., The safety of the blood supply-time to raise the bar. N Engl J Med 2015; 372: 1882-5.
2. McClaskey J, Xu M, Snyder EL, et al., Clinical trials for pathogen reduction in transfusion medicine: a review. Transfus Apher Sci 2009; 41: 217-25.
3. Conlan MG, Stassinopoulos A, Garratty G, et al., Antibody formation to S-303 treated RBCs in setting of chronic RBC transfusion [abstract]. Blood 2004; 104: 112a.
4. Seghatchian J, de Sousa G., Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006; 35: 189-96.
5. Benjamin RJ, McCullough J, Mintz PD, et al., Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45: 1739-49.
6. Kumar V, Lockerbie O, Keil SD, et al., Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80: 15-21.
7. Goodrich RP, Doane S, Reddy HL., Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38: 20-30.
8. Tonnetti L, Thorp AM, Reddy HL, et al., Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion 2012; 52: 409-16.
9. Tonnetti L, Thorp AM, Reddy HL, et al., Reduction of Leishmania donovani infectivity in whole blood using riboflavin and ultraviolet light. Transfusion 2015; 55: 326-9.
10. Keil SD, Bengrine A, Bowen R, et al., Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion 2015; 55: 1736-44.
11. Keil SD, Saakadze N, Bowen R, et al., Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products. Transfusion 2015; 55: 858-63.
12. Marschner S, Goodrich R., Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011; 38: 8-18.
13. Marschner S, Fast LD, Baldwin WM, et al., White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010; 50: 2489-98.
14. Jackman RP, Heitman JW, Marschner S, et al., Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion 2009; 49: 2686-99.
15. Jackman RP, Muench MO, Heitman JW, et al., Immune modulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice. Transfusion 2013; 53: 2697-709.
16. Fast LD, Dileone G, Li J, et al., Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006; 46: 642-8.
17. Blumberg N, Heal JM, Gettings KF., WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization. Transfusion 2003; 43: 945-52.
18. Singer ST, Wu V, Mignacca R, et al., Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood 2000; 96: 3369-73.
19. Hussein E, Desooky N, Rihan A, et al., Predictors of red cell alloimmunization in multitransfused Egyptian patients with β-thalassemia. Arch Pathol Lab Med 2014; 138: 684-8.
20. van de Watering L, Hermans J, Witvliet M, et al., HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: a randomized controlled trial. Transfusion 2003; 43: 765-71.
21. Schonewille H, Brand A., Alloimmunization to red blood cell antigens after universal leucodepletion. A regional multicentre retrospective study. Br J Haematol 2005; 129: 151-6.
22. Hendrickson JE, Hod EA, Spitalnik SL, et al., Leukoreduction decreases alloimmunogenicity of transfused murine RBCs. Blood 2009; 114: 646.
23. Ryder AB, Zimring JC, Hendrickson JE., Factors influencing RBC alloimmunization: lessons learned from murine models. Transfus Med Hemother 2014; 41: 406-19.
24. Goodrich RP, Murthy KK, Doane SK, et al., Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons. Transfusion 2009; 49: 64-74.
25. Cancelas JA, Rugg N, Fletcher D, et al., In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011; 51: 1460-8.
26. Okoye OT, Reddy H, Wong MD, et al., Large animal evaluation of riboflavin and ultraviolet light-treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model. Transfusion 2015; 55: 532-43.
27. Hendrickson JE, Hod EA, Spitalnik SL, et al., Storage of murine red blood cells enhances alloantibody responses to an erythroid-specific model antigen. Transfusion 2010; 50: 642-8.
28. Hendrickson JE, Hod EA, Cadwell CM, et al., Rapid clearance of transfused murine red blood cells is associated with recipient cytokine storm and enhanced alloimmunogenicity. Transfusion 2011; 51: 2445-54.
29. Hudson KE, Lin E, Hendrickson JE, et al., Regulation of primary alloantibody response through antecedent exposure to a microbial T-cell epitope. Blood 2010; 115: 3989-96.
30. Smith NH, Hod EA, Spitalnik SL, et al., Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood 2012; 119: 1566-9.
31. Asano H, Lee CY, Fox-Talbot K, et al., Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007; 84: 1174-82.
32. Stowell SR, Arthur CM, Girard-Pierce KR, et al., Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model. Haematologica 2015; 100: e394-7.
33. Pan XC, Deng YB, Sugawara Y, et al., Immunological behavior of enhanced green fluorescent protein (EGFP) as a minor histocompatibility antigen with a special reference to skin isograft and specific regulation of local graft-versus-host reaction (GvHR). Immunol Lett 2009; 123: 103-13.
34. Stripecke R, Carmen Villacres M, Skelton D, et al., Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 1999; 6: 1305-12.